Images | Sources | Experiment + Assay | Phenotypes | Human Diseases | ||||
---|---|---|---|---|---|---|---|---|
Fig. 7 CC'
Pera EM et al. (2024) |
Xal wt + Tg(Xla.hrta1-FLAG)
NF20-26 (in situ hybridization) |
|
||||||
Fig. 6 C C'
Pera EM et al. (2024) |
Xla Wt + htra1
NF20 (in situ hybridization) |
|
||||||
Fig. 8 D D'
Pera EM et al. (2024) |
Xla Wt + serpine2 MO
NF20-26 (in situ hybridization) |
|
||||||
Fig. 6 F F'
Pera EM et al. (2024) |
Xla wt + Tg(Xla.htra1-myc)
NF20-26 (in situ hybridization) |
|
||||||
Fig. 6 G G'
Pera EM et al. (2024) |
Xla wt + Tg(Xla.htra1-myc)del_PDZ
NF20-26 (in situ hybridization) |
|
||||||
Fig. 5 FG
Devotta A et al. (2023) |
Xla wt + A71915 (npr1 antagonist)
NF25 (in situ hybridization) |
|
||||||
Fig. 2 FG
Devotta A et al. (2023) |
Xla wt + AP-811 (npr3 antagonist)
NF25 (in situ hybridization) |
|
||||||
Fig. S6 FGH
Mishra-Gorur K et al. (2023) |
Xtr wt + Tg(traf)T601A
NF16-18 (in situ hybridization) |
|||||||
Fig. 2. U, V
Mishra-Gorur K et al. (2023) |
Xtr Wt + traf1
NF17 (in situ hybridization) |
|
||||||
Fig. 2. O
Mishra-Gorur K et al. (2023) |
Xtr wt + traf7 MO
NF16-18 (in situ hybridization) |
|